openPR Logo
Press release

Pulmonary Drugs Market Government Policies and Top Players Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals, AstraZenca., GlaxoSmithKline

05-27-2019 02:41 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Coherent Market Insights

Pulmonary Drugs

Pulmonary Drugs

Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated with the help of appropriate medication. This has led to intensification of efforts for development of effective and efficient pulmonary drugs and medications. Some of the pulmonary drugs are administered with the help of devices called nebulizers or inhalers.

The global pulmonary drugs market was valued at US$ 28.1 billion in 2016 and is expected to witness a robust CAGR of 8.1% over the forecast period (2017 - 2025).

Increasing incidence of Chronic Obstructive Pulmonary Disease (COPD) is directly proportional to the tobacco smoking and exposure. According to the World Health Organization (WHO) 2016, tobacco smoking is the primary cause of COPD leading to around 90% of COPD cases. The irreversible damages caused due to smoke leads to adoption of lifestyle adjustments and medical treatments that includes consumption of bronchodilators, inhaled glucocorticoids, inhaled steroids, and other pulmonary drugs to relieve the disease symptoms, thereby propelling demand for pulmonary drugs. Tobacco is major cause of death and illness across the world.

Request A Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/1285

The number of smokers is consistent globally and does not have a drop since a past few years. Smokers are highly susceptible to respiratory diseases such as COPD and asthma. For instance, according to the Centers of Disease Control and Prevention (CDC) the average rate of smokers in 2012 was 1 in 5 people, which was reported to be constant in the Burden of Tobacco use in the U.S. released in 2015. North America dominates the global pulmonary drugs market, owing to the increasing prescriptions of Inhaled corticosteroids (ICS) and Long-acting beta-agonists (LABA) combinational products. According to Ontario Drug Policy Research Network, 2015, ICS+LABA combination products are the second-most commonly prescribed inhaled respiratory medications for all indications in Canada, with 1.1 million prescriptions dispensed in the fourth quarter of 2013, whereas, short-acting beta-agonists (e.g., salbutamol) are the most frequently prescribed inhaled respiratory medications in Canada with 1.8 million prescriptions dispensed in the same time period.

Supportive government and non-government initiatives to accelerate the market growth

The government and non-government initiatives help patients to fight the diseases by providing sufficient medical care and education regarding the benefits of preventive measures as well as appropriate medications to curb the life threatening diseases such as COPD. For instance, in 2016, according to the World Health Organization (WHO), more than 90% of deaths were reported due to COPD in low and middle-income economies. Thus, the WHO initiated Global Alliance against Chronic Respiratory Diseases (GARD) with a vision to provide required medical treatments to patients suffering from chronic respiratory diseases in low and middle income economies. This provision demands a significant quantity of medication that is expected to propel the pulmonary drugs market. Also, in 2015, the Bill and Melinda Gates Foundation granted a US$ 89 Mn funding to Novavax, to develop RSV F (Respiratory Syncytial Virus) Vaccine for pregnant women in low sourced countries as maternal immunization vaccine to protect respiratory infections in the children.

Asia Pacific is expected to be the fastest growing region in the pulmonary drugs market, owing to the continuous marketing of new brands to consolidate and strengthen the sales of products by the manufacturers. For instance, in 2016, Lupin Limited and Novartis Healthcare Private Limited (NHPL) entered into a co-marketing agreement to promote Novartis’s Indacaterol / Glycopyrronium inhaler in India for treating COPD under the brand name of Loftair. The major players operating the global pulmonary drugs market include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1285

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pulmonary Drugs Market Government Policies and Top Players Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals, AstraZenca., GlaxoSmithKline here

News-ID: 1754655 • Views: 297

More Releases from Coherent Market Insights

Virtual Data Room Market With Top Companies Ansarada, Brainloop virtual data roo …
North America is expected to be dominant in the global virtual data room market over the forecast period. Due to the massive growth in the business deals and transactions, such as mergers and acquisitions, joint ventures, and fundraising across the region due to the rapid expansion of SMEs (small and medium) enterprises as well as the higher development of infrastructure. 𝑻𝒉𝒆 π’Žπ’‚π’Šπ’ π’Œπ’†π’š π’‘π’π’‚π’šπ’†π’“π’” π’Šπ’ 𝒕𝒉𝒆 π’Šπ’π’…π’–π’”π’•π’“π’š 𝒂𝒓𝒆- Ansarada, Brainloop…
Cloud Analytics Market With Top Companies Google, Vmware., Tibco, Teradata, Tabl …
The North America held a dominant position in the global cloud analytics market in 2016. Organisation shifting their workload in the cloud is one of the major driving factor for the growth of the market. According to the Coherent Market Insights analysis, in 2015, the cloud traffic was 1891 EB (Exabyte) and is estimated to reach 6844EB (Exabyte) by 2020. Therefore, with increase in cloud traffic requirement of analytics tools…
Global Customer Relationship Management Market With Top Companies Oracle, SAP SE …
On the basis of geography, the global customer relationship management market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America held the dominant position in the market in 2016 and is projected to retain its dominance throughout the forecast period. The U.S. and Canada are some of the major growth engines in this region. 𝑻𝒉𝒆 π’Žπ’‚π’Šπ’ π’Œπ’†π’š π’‘π’π’‚π’šπ’†π’“π’” π’Šπ’ 𝒕𝒉𝒆 π’Šπ’π’…π’–π’”π’•π’“π’š 𝒂𝒓𝒆- Oracle Corporation,…
Data Center Security Market With Top Companies Symantec, Juniper Networks, Alleg …
On basis of geography, the data center security market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is expected to account for the largest share in the data center security market, due to high adoption of the cloud computing solutions and increasing number of data centers in the region. 𝑻𝒉𝒆 π’Žπ’‚π’Šπ’ π’Œπ’†π’š π’‘π’π’‚π’šπ’†π’“π’” π’Šπ’ 𝒕𝒉𝒆 π’Šπ’π’…π’–π’”π’•π’“π’š 𝒂𝒓𝒆- Symantec Corporation, Juniper Networks…

All 5 Releases


More Releases for Pulmonary

Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary Drugs Market – Boon for Diseased Lungs Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Global Pulmonary Arterial Hypertension Market to 2024
Global Pulmonary Arterial Hypertension (PAH) market was valued at $5.0bn in 2015 and is forecast to grow at a modest 6.0% CAGR between 2015 and 2024, to result in 2024 global sales of $9.0bn. PAH is broadly split into two classes, primary or secondary. Primary pulmonary hypertension (PPH) refers to pulmonary hypertension occurring without an identifiable cause. Secondary pulmonary arterial hypertension (PAH) occurs in association with some other identifiable medical condition. …
Pulmonary Fibrosis Market Professional Survey Report 2017
Global Pulmonary Fibrosis Market: Snapshot Pulmonary fibrosis belongs to the family of interstitial diseases that can lead to damage of the lungs. As the lung tissue becomes stiff and thickened, it interferes with a person’s ability to breathe. The scarring of lung tissues is associated with a multitude of factors. However, in most cases, the cause of the problem can’t be determined. This state is termed as idiopathic pulmonary fibrosis. While the…
Pulmonary Drugs 2024 Market Research Report
Global Pulmonary Drugs Market: Snapshot The global pulmonary drugs market has been the key area of focus and the most crucial market for the healthcare industry in the last couple of years. However, the market is expected to witness a significant decline over the forecast period with a -6.3% CAGR from 2016 to 2024. The market is anticipated to fall to US$28,082.1 mn from a valuation of US$48,039.7 mn in…
Latest Report: Global Pulmonary Hypertension Market
MarketResearchReports.Biz presents this most up-to-date research on "Pulmonary Hypertension-Pipeline Insights, 2017" DelveInsights, Pulmonary Hypertension-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Pulmonary Hypertension. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations,…